Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes

被引：0
|
作者：
Astrup, A. V. [1 ]
Oppert, J. -M. [2 ]
Peterson, C. A. [3 ]
机构：
[1] Univ Copenhagen, LIFE, Dept Human Nutr, Frederiksberg, Denmark
[2] Univ Paris 06, Dept Nutr, Paris, France
[3] Vivus Inc, Mountain View, CA USA
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
695
引用
收藏
页码：S284 / S285
页数：2
相关论文
共 50 条
  • [1] WEIGHT LOSS WITH PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE IN OBESE AND OVERWEIGHT SUBJECTS OVER 56 WEEKS
    Kushner, Robert F.
    Varghese, Santosh T.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S241 - S241
  • [2] Effects of extended-release phentermine/topiramate on weight loss and blood pressure in obese subjects with type 2 diabetes mellitus
    Rossner, S. K.
    Sharma, A. M.
    Troupin, B.
    Padwal, R. S.
    DIABETOLOGIA, 2012, 55 : S285 - S285
  • [3] EFFECTS OF WEIGHT LOSS ON PREVENTION OF TYPE 2 DIABETES MELLITUS IN SUBJECTS WITH PREDIABETES USING PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE FOR 2 YEARS
    Kushner, Robert F.
    Garvey, W. Timothy
    Peterson, Craig A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S71 - S71
  • [4] Evaluation of Phentermine and Topiramate versus Phentermine/Topiramate Extended-Release in Obese Adults
    Aronne, Louis J.
    Wadden, Thomas A.
    Peterson, Craig
    Winslow, David
    Odeh, Sarah
    Gadde, Kishore M.
    OBESITY, 2013, 21 (11) : 2163 - 2171
  • [5] CARDIOVASCULAR EFFECTS BASED ON MAGNITUDE OF WEIGHT LOSS (WL) IN OBESE/OVERWEIGHT SUBJECTS WITH HYPERTENSION RECEIVING PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
    Bakris, George
    Davidson, Michael H.
    Gupta, Alok K.
    JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (07): : 517 - 517
  • [6] Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
    Garvey, W. Timothy
    Ryan, Donna H.
    Bohannon, Nancy J. V.
    Kushner, Robert F.
    Rueger, Miriam
    Dvorak, Roman V.
    Troupin, Barbara
    DIABETES CARE, 2014, 37 (12) : 3309 - 3316
  • [7] Clinically Meaningful Weight-Loss Outcomes With Low-Dose Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects
    Gadde, Kishore M.
    Peterson, Craig
    Day, Wesley W.
    OBESITY, 2010, 18 : S153 - S153
  • [8] COMORBIDITY COST SAVINGS OVER 2 YEARS OF TREATMENT WITH PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) IN AN OVERWEIGHT AND OBESE POPULATION
    Carlton, R.
    Zagadailov, E.
    Bramley, T.
    Liu, W.
    Kamawat, S.
    McDowell, J.
    VALUE IN HEALTH, 2014, 17 (03) : A108 - A108
  • [9] BUDGET IMPACT OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) IN OVERWEIGHT AND OBESE PATIENTS WITH COMORBID PREDIABETES OR TYPE 2 DIABETES MELLITUS (T2DM)
    Zagadailov, E.
    Carlton, R.
    Bramley, T.
    Liu, W.
    Karnawat, S.
    McDowell, J.
    VALUE IN HEALTH, 2014, 17 (03) : A242 - A242
  • [10] Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
    Garvey, W. Timothy
    Ryan, Donna H.
    Henry, Robert
    Bohannon, Nancy J. V.
    Toplak, Hermann
    Schwiers, Michael
    Troupin, Barbara
    Day, Wesley W.
    DIABETES CARE, 2014, 37 (04) : 912 - 921
12345